Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 3/20 | 0.42 |
| ▸ | AXL | P30530 | 6/20 | 0.41 |
| ▸ | MERTK | Q12866 | 5/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24148625 | 0.82 | AXL (0.46) | GPR119USP30RETAXLLRRK2 | |
| SCHEMBL8820197 | 0.80 | GPR119 (0.46) | GPR119USP30NR3C1 | |
| SCHEMBL8818888 | 0.79 | GPR119 (0.44) | GPR119USP30 | |
| SCHEMBL7350588 | 0.79 | GPR119 (0.49) | GPR119USP30NR3C1PIK3CAPIK3CG | |
| SCHEMBL7344659 | 0.79 | GPR119 (0.53) | GPR119USP30NR3C1 | |
| SCHEMBL31583380 | 0.79 | GPR119 (0.44) | GPR119USP30NR3C1 | |
| SCHEMBL15656816 | 0.78 | GPR119 (0.44) | GPR119BTKUSP30NR3C1 | |
| SCHEMBL31565532 | 0.77 | CREBBP (0.67) | — | |
| SCHEMBL10060450 | 0.77 | GPR119 (0.68) | GPR119USP30NR3C1PIK3CAMTOR | |
| SCHEMBL29507014 | 0.77 | GPR119 (0.68) | GPR119USP30NR3C1PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025081082-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | GPR119 245/4885BTK 1838/4885USP30 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.